Puma Biotechnology Announces Presentation of Findings from a Phase I/II Study of Alisertib and Pembrolizumab for Rb-Deficient Head and Neck Squamous Cell Carcinomas at the 2023 AACR-NCI-EORTC Molecular Targets and Cancer Therapeutics Meeting

LOS ANGELES–(BUSINESS WIRE)–Puma Biotechnology reported findings from a Phase I/II study of Alisertib and pembrolizumab for Rb-Deficient HNSCC at the 2023 AACR-NCI-EORTC meeting
Click here to view original post